MarginsXMarginsX
Home › Markets › Health Care › ENVB

Enveric Biosciences Inc. (ENVB)

ENVB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.44
-4.95% on the day
Market cap
$6.4M
Nano cap
Revenue · 2019
$39.9M
No prior year to compare
Net income · 2019
-$2.4M
-6.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2019-12-31, https://www.sec.gov/Archives/edgar/data/890821/000114036120006825/0001140361-20-006825-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2019-12-31.

Profile

FieldValue
TickerENVB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000890821
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2019

LineValue
Revenue$39.9M
Net income-$2.4M
Operating income-$2.3M
Net margin-6.0%
Operating margin-5.8%
Revenue growthNo prior-year revenue to compare
Cash$431K
Total assets$109K
P/E (computed)Net income was not positive
P/S (computed)0.2×

Warning signs

Cash runway
11.6 months
$8.3M cash at June 30, 2026
Share count, 1 year
+649.8%
2025-11-12 to 2026-11-11 · +520505.2% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements."
10-Q 2026-11-13
Cash and burn$8.3M cash; operating cash flow -$2.1M a quarter.Report 2026-06-30
Shares outstanding4,475,884 (2026-11-11); 596,978 a year earlier; 2,321,315 three years earlier. 3y figure adjusted for splits (1-for-2700 overall).Cover page 2026-11-11
Reverse splits, 3 years3; latest 1-for-12 on 2025-10-28Source 2025-10-28
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-06-09
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCBIZ CPAs P.C., Morristown, New Jersey, United States; changed auditors 1 time in 24 months8-K 4.01 2025-04-14
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$3.0M-$2.4M$8.3MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$1.6M-$2.3M$4.9MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$2.2M-$1.8M$4.7MNo debt tagsNeeds four quarters10-K 2026-03-27
Q3 2025
2025-09-30
Not filed-$1.9M-$2.1M$3.8MNo debt tagsNeeds four quarters10-Q 2025-11-14
Q2 2025
2025-06-30
Not filed-$2.5M-$1.9M$2.8MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$2.2M-$2.4M$4.3MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-12-31
Not filed-$3.2M-$1.3M$2.2MNo debt tagsNeeds four quarters10-K 2026-03-27
Q3 2024
2024-09-30
Not filed-$2.1M-$927K$3.1MNo debt tagsNeeds four quarters10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-06-09
Latest annual report10-K2026-03-27
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-13
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+6.4%
1 month+8.2%
3 months+0.3%
Year to date-58.3%
1 year-72.3%
From 52-week high-85.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
TOVXTheriva Biologics Inc.$0.1400-2.85%$6.4M
ADXNAddex Therapeutics Ltd$3.83-5.67%$6.5M
TCRTAlaunos Therapeutics Inc.$1.60-1.84%$6.7M
SNGXSoligenix Inc.$0.2882-10.22%$6.7M
FBLGFibroBiologics Inc.$0.9034-2.00%$6.1M
TPSTTempest Therapeutics Inc.$0.3418-10.50%$6.8M
XCURExicure Inc.$1.07-0.93%$7.0M
LTRNLantern Pharma Inc.$0.3890-10.18%$5.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier